

**General information about company**

Name of The Company	BAFNA PHARMACEUTICALS LIMITED
BSE Scrip Code	532989
NSE Symbol	BAFNAPH
MSE Symbol	NA
Date of Start of Financial Year	01-04-2022
Date of End of Financial Year	31-03-2023
Reporting Period	Second half yearly
Date of Start of Reporting Period	01-10-2022
Date of End of Reporting Period	31-03-2023
Level of rounding to be used in disclosing related party transactions	Millions
Whether the company has any related party?	Yes
Whether the company has entered into any Related Party transaction during the selected half year for which it wants to submit disclosure?	Yes

(I) We declare that the acceptance of fixed deposits by the banks/Non-Banking Finance Company are at the terms uniformly applicable/offered to all shareholders/public	NA
(II) We declare that the scheduled commercial bank, as per RBI circular RBI/DBR/2015-16/19 dated March 03, 2016, has allowed additional interest of one per cent per annum, over and above the rate of interest mentioned in the schedule of interest rates on savings or a term deposits of bank's staff and their exclusive associations as well as on deposits of Chairman, Chairman & Managing Director, Executive Director or such other Executives appointed for a fixed tenure.	NA
(III) Whether the company is a 'high value debt listed entity' according to regulation 15 (1A)?	No
(a) If answer to above question is Yes, whether complying with proviso to regulation 23 (9), i.e., submitting RPT disclosures on the day of results publication?	
<b>(b) If answer to above question is No, please explain the reason for not complying.</b>	

**Related party transactions**

Sr No.	Details of the party (listed entity /subsidiary) entering into the transaction		Details of the counterparty			Type of related party transaction	Details of other related party transaction	Value of the related party transaction as approved by the audit committee	Remarks on approval by audit committee	Value of transaction during the reporting period
	Name	PAN	Name	PAN	Relationship of the counterparty with the listed entity or its subsidiary					
1	BAFNA PHARMACEUTICALS LIMITED	AAACB3109Q	Bafna Mahaveer Chand	AACP6411G	Chief Executive officer	Any other transaction	Rendering Services		Approved	1.8
2	BAFNA PHARMACEUTICALS LIMITED	AAACB3109Q	Bafna Mahaveer Chand	AACP6411G	Chief Executive officer	Any other transaction	Loan		Approved	-0.249
3	BAFNA PHARMACEUTICALS LIMITED	AAACB3109Q	Bafna Mahaveer Chand	AACP6411G	Chief Executive officer	Any other transaction	Salary Advance		Approved	0.1
4	BAFNA PHARMACEUTICALS LIMITED	AAACB3109Q	Navin Bafna	APIP8787J	Head Business Development	Any other transaction	Rendering Services		Approved	1.2
5	BAFNA PHARMACEUTICALS LIMITED	AAACB3109Q	Navin Bafna	APIP8787J	Head Business Development	Any other transaction	Salary Advance		Approved	0.304
6	BAFNA PHARMACEUTICALS LIMITED	AAACB3109Q	Sasikala Bafna	AASPB2718E	Relative of KMP	Any other transaction	Lease		Approved	0.885
7	BAFNA PHARMACEUTICALS LIMITED	AAACB3109Q	M Sridhar	BZKPS2221P	Chief Financial Officer	Remuneration			Approved	0.593
8	BAFNA PHARMACEUTICALS LIMITED	AAACB3109Q	M Sridhar	BZKPS2221P	Chief Financial Officer	Any other transaction	Salary Advance		Approved	0.084
9	BAFNA PHARMACEUTICALS LIMITED	AAACB3109Q	S Hemalatha	AAWPH3452M	Executive Director	Remuneration			Approved	0.748
10	BAFNA PHARMACEUTICALS LIMITED	AAACB3109Q	S Hemalatha	AAWPH3452M	Executive Director	Any other transaction	Salary Advance		Approved	0.108
11	BAFNA PHARMACEUTICALS LIMITED	AAACB3109Q	PK Sundaresan	AIZPS7199D	Independent Director	Any other transaction	Sitting Fees		Approved	0.066
12	BAFNA PHARMACEUTICALS LIMITED	AAACB3109Q	B Kamlesh Kumar	AADPK2196G	Independent Director	Any other transaction	Sitting Fees		Approved	0.066
13	BAFNA PHARMACEUTICALS LIMITED	AAACB3109Q	R Chitra	AAFPC1741D	Independent Director	Any other transaction	Sitting Fees		Approved	0.055
14	BAFNA PHARMACEUTICALS LIMITED	AAACB3109Q	Akila C Raju	ARNPR7975B	Non-Independent Director	Any other transaction	Sitting Fees		Approved	0.044
15	BAFNA PHARMACEUTICALS LIMITED	AAACB3109Q	Saffolco Pharmachem LLP	AECFS8769N	Enterprise in which KMP is Interested	Any other transaction	Advance for Service		Approved	-1.95
16	BAFNA PHARMACEUTICALS LIMITED	AAACB3109Q	SMN Pharma Private Limited	ABDCS5871J	Enterprise in which KMP is Interested	Any other transaction	Advance for Service		Approved	-1.595
17	BAFNA PHARMACEUTICALS LIMITED	AAACB3109Q	Ruchika Saraf	FDMP5659R	Relative of KMP	Any other transaction	Advance for Service		Approved	-2

Total value of transaction during the

0.258999999999999



